Brief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
07/05/2025 13:32
Hepion Pharmaceuticals Inc HEPA.O: HEPION PHARMACEUTICALS EXECUTES BINDING LETTER OF INTENT WITH NEW DAY DIAGNOSTICS TO COMMERCIALIZE DIAGNOSTIC TESTS FOR CELIAC DISEASE, RESPIRATORY MULTIPLEX, H. PYLORI AND HCC Source text: ID:nGNX8mKlh7 Further company coverage: HEPA.O
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement